Sugi Predict

Sugi Predict / Targets / CCNC

CCNC

Cyclin-C · P24863 · CCNC on Sugi Atlas →

53,070 patent compounds predicted against CCNC, 24,621 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL578403 SCHEMBL578403 0.67 16/20
SCHEMBL578754 SCHEMBL578754 0.52 16/20
SCHEMBL1006232 SCHEMBL1006232 0.64 15/20
SCHEMBL1006234 SCHEMBL1006234 0.64 15/20
SCHEMBL578607 SCHEMBL578607 0.59 14/20
SCHEMBL348179 SCHEMBL348179 0.54 14/20
SCHEMBL578764 SCHEMBL578764 0.56 13/20
SCHEMBL578632 SCHEMBL578632 0.54 13/20
SCHEMBL660279 SCHEMBL660279 0.63 10/20
SCHEMBL743165 SCHEMBL743165 0.45 10/20
SCHEMBL1019077 SCHEMBL1019077 0.64 9/20
SCHEMBL578414 SCHEMBL578414 0.60 9/20
SCHEMBL1006747 SCHEMBL1006747 0.44 9/20
SCHEMBL253500 SCHEMBL253500 0.40 9/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL1020377) 0.57 8/20
SCHEMBL578476 SCHEMBL578476 0.49 8/20
SCHEMBL717713 SCHEMBL717713 0.51 7/20
SCHEMBL966355 SCHEMBL966355 0.46 7/20
SCHEMBL966357 SCHEMBL966357 0.46 7/20
SCHEMBL1034211 SCHEMBL1034211 0.56 6/20

Clinical trials — most relevant to CCNC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer PHASE4NOT_YET_RECRUITING
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma PHASE1/PHASE2RECRUITING
Palbociclib and Pembrolizumab In Central Nervous System Metastases PHASE2RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. PHASE1/PHASE2COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors PHASE2WITHDRAWN
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors PHASE1/PHASE2COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer PHASE1ACTIVE_NOT_RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma PHASE1COMPLETED
Erlotinib in Treating Patients With Barrett Esophagus PHASE1UNKNOWN
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA PHASE1RECRUITING
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC PHASE1WITHDRAWN
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer nanCOMPLETED
The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence nanUNKNOWN
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma nanCOMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CCNC binder may also engage these)

ProteinNameSimilarity
Q3ZCK5 — 1.000 Q3ZCK5 →
Q62447 — 1.000 Q62447 →
Q4KLA0 — 1.000 Q4KLA0 →
Q28F72 — 1.000 Q28F72 →
P55168 — 1.000 P55168 →
P39947 — 0.984 P39947 →
Q5R532 — 0.926 Q5R532 →
Q5F398 — 0.925 Q5F398 →
COPS2 COP9 signalosome complex subunit 2 0.923 landscape →
Q4R9A8 — 0.921 Q4R9A8 →
Q4VC33 — 0.921 Q4VC33 →
Q5R8K2 — 0.921 Q5R8K2 →
Q99LC2 — 0.920 Q99LC2 →
Q5BJQ6 — 0.920 Q5BJQ6 →
Q7SXR3 — 0.919 Q7SXR3 →
P61203 — 0.919 P61203 →
Q05048 — 0.919 Q05048 →
Q32NS4 — 0.918 Q32NS4 →
Q6IQT4 — 0.918 Q6IQT4 →
Q7L5Y9 — 0.918 Q7L5Y9 →
Q3UHD6 — 0.917 Q3UHD6 →
Q6IR75 — 0.917 Q6IR75 →
B1H1E4 — 0.917 B1H1E4 →
A5PKA5 — 0.917 A5PKA5 →
Q9UL63 — 0.917 Q9UL63 →
P61202 — 0.917 P61202 →
Q6GR10 — 0.916 Q6GR10 →
Q9UKF6 — 0.915 Q9UKF6 →
O89050 — 0.915 O89050 →
Q6PFJ9 — 0.915 Q6PFJ9 →